About orion oyj - ORINF
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.
ORINF At a Glance
Orion Oyj
Orionintie 1A
Espoo, Uusimaa 02200
| Phone | 358-10-4261 | Revenue | 2.13B | |
| Industry | Pharmaceuticals: Major | Net Income | 564.63M | |
| Sector | Health Technology | 2025 Sales Growth | 27.782% | |
| Fiscal Year-end | 12 / 2026 | Employees | 4,029 | |
| View SEC Filings |
ORINF Valuation
| P/E Current | 19.995 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.622 |
| Price to Sales Ratio | 4.935 |
| Price to Book Ratio | 6.972 |
| Price to Cash Flow Ratio | 29.41 |
| Enterprise Value to EBITDA | 13.896 |
| Enterprise Value to Sales | 5.015 |
| Total Debt to Enterprise Value | 0.034 |
ORINF Efficiency
| Revenue/Employee | 528,798.574 |
| Income Per Employee | 140,140.866 |
| Receivables Turnover | 2.52 |
| Total Asset Turnover | 1.047 |
ORINF Liquidity
| Current Ratio | 2.399 |
| Quick Ratio | 1.585 |
| Cash Ratio | 0.287 |
ORINF Profitability
| Gross Margin | 62.93 |
| Operating Margin | 33.107 |
| Pretax Margin | 33.256 |
| Net Margin | 26.502 |
| Return on Assets | 27.746 |
| Return on Equity | 44.297 |
| Return on Total Capital | 30.238 |
| Return on Invested Capital | 37.737 |
ORINF Capital Structure
| Total Debt to Total Equity | 23.776 |
| Total Debt to Total Capital | 19.209 |
| Total Debt to Total Assets | 15.094 |
| Long-Term Debt to Equity | 8.976 |
| Long-Term Debt to Total Capital | 7.252 |